Streetbeat News

Regulatory

MPC

Marathon Petroleum Corporation's (MPC) Galveston Bay, Texas, Fluid Catalytic Cracking (FCC) unit remains shut following a fire. The U.S. Occupational Safety and Health Administration (OSHA) is set to begin an investigation into the incident.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 1:50 pm

TCOA

Shares of Zalatoris Acquisition Corp. have been halted due to pending news. The nature of the news is not yet disclosed.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 1:41 pm

LLY

NVO

UK's National Institute for Health and Care Excellence (NICE) has endorsed Eli Lilly's diabetes medication, Mounjaro, as a viable treatment for type 2 diabetes. This comes amid national shortages of Novo Nordisk's Ozempic, a similar drug. NICE estimates that around 180,000 individuals could benefit from Mounjaro. The drug has also shown potential in combating obesity. The final guidance from NICE is expected on October 11, after which Mounjaro will be available within the UK's National Health Service.

Portfolio Pulse from Vandana Singh

September 08, 2023 | 1:38 pm

BBBY

JPM

NVDA

TSLA

JPMorgan is reportedly working on a blockchain payment system, which has led to a spike in Bitcoin, Ethereum, and Dogecoin. Tesla's Supercharger network has expanded to 50,000 stations worldwide. NVIDIA and Reliance Industries are collaborating to create AI infrastructure. Goldman Sachs is planning further workforce reductions after earlier layoffs. Ryan Cohen is reportedly under SEC investigation over his trades in Bed Bath & Beyond.

Portfolio Pulse from Akanksha Bakshi

September 08, 2023 | 1:34 pm

INBS

Intelligent Bio Solutions Inc. (NASDAQ:INBS) has completed a key development milestone in its plans to add ketamine and tramadol to its Intelligent Fingerprinting Drug Screening System. The new assays for testing both drugs have passed the initial design phase and are ready for scale-up and transfer to manufacture in preparation for potential clinical trials. The system is portable, non-invasive, fast, and cost-effective, with applications in various sectors.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 1:05 pm

ONDS

PRZO

The Airobotics Optimus-1EX Uncrewed Aircraft System, a drone designed for autonomous security and data capture, has been granted Type Certification by the Federal Aviation Administration (FAA). This is a historic milestone as it streamlines operational approvals for broad flight operations. The drone uses a safety system from ParaZero Technologies Ltd. (NASDAQ:PRZO), an aerospace company focused on drone safety systems. Airobotics is a subsidiary of Ondas Holdings Inc. (NASDAQ:ONDS), a provider of private industrial wireless networks, commercial drones and automated data solutions.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 12:56 pm

AMZN

CMCSA

DIS

NFLX

PARA

SONY

WMD

Israel has partnered with Russia in a filmmaking pact, drawing backlash amid the ongoing conflict with Ukraine. Major U.S. film companies, including Netflix, Amazon, Warner Bros. Discovery, Disney, Sony, Paramount Global, and Comcast, have stopped releasing movies in Russia and some have left the country completely. The partnership between Israel and Russia could potentially impact movie and television companies partnered in Israel or on Israeli films, as they may face difficult decisions regarding films that could end up being screened in or financed by Russia.

Portfolio Pulse from Chris Katje

September 08, 2023 | 12:52 pm

CALT

TVTX

XBI

Swedish biopharma Calliditas Therapeutics AB (NASDAQ:CALT) is making progress in addressing rare kidney diseases with its lead drug, Tarpeyo. The drug has received accelerated FDA approval for treating IgA nephropathy, an autoimmune kidney disorder. Tarpeyo focuses on the origin of the disease and is delivered to the gut. The CEO of Calliditas, Renee Aguiar-Lucander, highlighted two key differentiators for Tarpeyo versus other approaches in chronic kidney disease treatment. The drug can stabilize kidney function and gives the freedom of not necessarily staying on it for the rest of a patient's life. The company is also close to profitability and has a healthy cash balance.

Portfolio Pulse from Shanthi Rexaline

September 08, 2023 | 12:42 pm

CRMD

CorMedix Inc. (NASDAQ:CRMD) has announced the publication of its Phase 3 LOCK IT-100 study results in the Clinical Journal of the American Society of Nephrology. The study demonstrated a significant 71% reduction in risk of developing Catheter Related Bloodstream Infections (CRBSIs) in subjects receiving hemodialysis via central venous catheter (CVC) using DefenCath, a catheter lock solution. The company is pursuing FDA approval of DefenCath, with a target action date of November 15, 2023.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 12:35 pm

BLK

FXI

China's Securities Regulator has held discussions with both domestic and overseas investors, including Temasek, Bridgewater, and BlackRock. The details of the discussions were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 12:19 pm